Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (Clinical and Translational Oncology, (2019), 10.1007/s12094-019-02166-z)

Research output: Contribution to journalComment/debate


Acknowledgements section was missing in the original published version. The Acknowledgement section read as follows: Acknowledgements FB supported by AIRC IG 20109.

Original languageEnglish
JournalClinical and Translational Oncology
Publication statusAccepted/In press - Jan 1 2019


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this